for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evotec SE

EVTG.DE

Latest Trade

18.55EUR

Change

-0.61(-3.18%)

Volume

2,426,301

Today's Range

18.55

 - 

19.30

52 Week Range

16.23

 - 

27.29

As of on the XETRA ∙ Minimum 15 minute delay

Latest Developments

Merck Signs License Agreement With Evotec

Nov 12 (Reuters) - MERCK KGAA <MRCG.DE>::IT HAS SIGNED A LICENSE AGREEMENT PROVIDING EVOTEC SE ACCESS TO MERCK’S FOUNDATIONAL CRISPR INTELLECTUAL PROPERTY.

Evotec Raises 2019 EBITDA Guidance, Confirms Revenue Outlook

Nov 12 (Reuters) - Evotec SE <EVTG.DE>::EVOTEC SE REPORTS FIRST NINE-MONTH 2019 RESULTS AND CORPORATE UPDATES.16% INCREASE IN GROUP REVENUES, 36% GROWTH IN ADJUSTED GROUP EBITDA.REVENUE GUIDANCE FOR FULL-YEAR 2019 CONFIRMED; EBITDA GUIDANCE INCREASED TO APPROXIMATELY 15%; PROMISING INITIAL OUTLOOK FOR 2020.ADJUSTED GROUP EBITDA UP 36% TO EUR 93.2 M (9M 2018: EUR 68.7 M).UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES OF EUR 25.7 M (9M 2018: EUR 16.0 M).FULL-YEAR 2019 GUIDANCE FOR REVENUE AND UNPARTNERED RESEARCH AND DEVELOPMENT COSTS CONFIRMED; EBITDA GUIDANCE INCREASED TO APPROXIMATELY 15% (PREVIOUSLY: >10%).REVENUE INCREASE IN 9M MAINLY DUE TO VERY STRONG PERFORMANCE IN BASE BUSINESS ACROSS ALL BUSINESS LINES, SOLID MILESTONE PAYMENTS, AND FIRST REVENUE CONTRIBUTIONS BY JUST - EVOTEC BIOLOGICS.GROSS MARGIN IN FIRST NINE MONTHS OF 2019 AMOUNTED TO 30.7% (9M 2018: 30.1%).IMPAIRMENTS OF INTANGIBLE ASSETS AND GOODWILL OF EUR 11.9 M WERE RECORDED (9M 2018: IMPAIRMENT OF INTANGIBLE ASSETS OF EUR 4.2 M). THIS ONE-OFF IMPAIRMENT WAS MAINLY DUE TO TERMINATION OF SGM-1019 AGREEMENT BY OUR PARTNER SECOND GENOME.

Evotec Announces Partnership With Integra Holdings, Yissum

Oct 23 (Reuters) - Evotec SE <EVTG.DE>::EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT.FIRST ACADEMIC BRIDGE PARTNERSHIP IN ISRAEL AIMS TO TRANSLATE EARLY-STAGE RESEARCH FROM HEBREW UNIVERSITY ("HU") OF JERUSALEM INTO INDUSTRIAL DRUG DEVELOPMENT PROJECTS.LAB555 LEVERAGES INTEGRA'S SKILL IN IDENTIFYING AND DEVELOPING PROMISING EARLY-STAGE THERAPEUTIC PROJECTS, YISSUM'S TRANSLATIONAL EXPERTISE AND EVOTEC'S INDUSTRIAL DRUG DEVELOPMENT PLATFORM.NO FINANCIAL DETAILS OF COLLABORATION WERE DISCLOSED.

Evotec And Celmatix Enter Into Collaboration

Oct 9 (Reuters) - Evotec SE <EVTG.DE>::DGAP-NEWS: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION.PARTNERSHIP TO DEVELOP PRE-CLINICAL PROGRAMMES IN PREVALENT BUT UNDERSERVED CONDITIONS AFFECTING WOMEN'S REPRODUCTIVE HEALTH, INCLUDING POLYCYSTIC OVARY SYNDROME ("PCOS"), ENDOMETRIOSIS, AND INFERTILITY.NO FINANCIAL TERMS OF THIS COLLABORATION WERE DISCLOSED.

Evotec, Takeda Enter Collaboration Across Multiple Therapeutic Fields

Sept 24 (Reuters) - Evotec Se <EVTG.DE>::DGAP-NEWS: EVOTEC AND TAKEDA ENTER COLLABORATION AGREEMENT TO DISCOVER CLINICAL CANDIDATES ACROSS MULTIPLE THERAPEUTIC AREAS.MULTI-YEAR SMALL MOLECULE DRUG DISCOVERY COLLABORATION WITH A RISK SHARING, SUCCESS DRIVEN MODEL.EVOTEC LEADS INTEGRATED PROGRAMMES WITH TAKEDA HAVING OPTIONS AT LEAD SERIES AND CANDIDATE.EVOTEC RECEIVES UNDISCLOSED UPFRONT PAYMENT AND CAN EARN FUTURE MILESTONE AND ROYALTY PAYMENTS.PARTIES AIM TO ESTABLISH AT LEAST FIVE DRUG DISCOVERY PROGRAMMES WITH GOAL OF EVOTEC DELIVERING CLINICAL CANDIDATES FOR TAKEDA TO PURSUE INTO CLINICAL DEVELOPMENT.EVOTEC IS ELIGIBLE TO RECEIVE PRE-CLINICAL, CLINICAL, AND COMMERCIAL MILESTONES THAT CAN TOTAL IN EXCESS OF $ 170 M PER PROGRAMME AS WELL AS TIERED ROYALTIES ON FUTURE SALES.

Evotec Lifts Guidance, Sees F-Y Operating Profit Rising by Over 10% After H1

Aug 14 (Reuters) - Evotec SE <EVTG.DE>::H1 REVENUE ROSE 16 PERCENT TO 207.1 MILLION EUR.DGAP-NEWS: EVOTEC SE REPORTS FIRST HALF-YEAR 2019 RESULTS AND CORPORATE UPDATES.STRONG OUTLOOK FOR YEAR - GUIDANCE INCREASED.STRONG FIRST HALF YEAR WITH 16% INCREASE IN GROUP REVENUES, 51% EBITDA.GROUP REVENUES UP 16% TO EUR 207.1 M (H1 2018: EUR 178.9 M).ADJUSTED GROUP EBITDA UP 51% TO EUR 58.2 M (H1 2018: EUR 38.6 M).UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES OF EUR 18.7 M (H1 2018: EUR 10.0 M).GROUP REVENUES FROM CONTRACTS WITH CUSTOMERS WITHOUT REVENUES FROM RECHARGES ARE EXPECTED TO INCREASE BY APPROX. 15% (PREVIOUSLY: APPROX. 10%) (2018: EUR 364.0 M).ADJUSTED GROUP EBITDA IS EXPECTED TO INCREASE BY >10% (PREVIOUSLY: APPROX. 10%) (2018: EUR 92.0 M).GUIDANCE ON UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES REMAINS UNCHANGED AT EUR 30-40 M (2018: EUR 22.9 M).

Evotec And Lygature In Cooperation To Develop Antibacterial Agents

Aug 1 (Reuters) - EVOTEC SE <EVTG.DE>::EVOTEC SE AND LYGATURE ANNOUNCED COOPERATION FOR DEVELOPMENT OF ANTIBACTERIAL AGENTS.TO DO 3 PROGRAMS, 1 TO COMPLETE PHASE I STUDIES, 1 TO INVESTIGATIONAL NEW DRUG (IND) STAGE AND/OR UP TO 2 REACHING CLINICAL DEVELOPMENT CANDIDATE STAGE, BY 2024.IMI, WORLD'S LARGEST PUBLIC-PRIVATE PARTNERSHIP (PPP) IN LIFE SCIENCES, WILL MATCH EVOTEC'S IN-KIND CONTRIBUTION WITH A EUR 12 M GRANT OVER NEXT SIX YEARS.

Evotec: Positive Phase II Data For P2x3 Antagonist

July 25 (Reuters) - EVOTEC SE <EVTG.DE>::POSITIVE PHASE II DATA FOR P2X3 ANTAGONIST IN PATIENTS WITH REFRACTORY CHRONIC COUGH.UNDERLYING MOLECULE IS A P2X3 ANTAGONIST ORIGINATING FROM EVOTEC/BAYER MULTI-TARGET ALLIANCE.PRELIMINARY EVALUATION INDICATED THAT ALL PRIMARY ENDPOINTS HAVE BEEN MET AND THAT IN STUDY BAY1817080 WAS FOUND TO BE SAFE AND WELL TOLERATED.

Evotec SE Acquires Assets From Stem Cell Specialist Ncardia AG

July 15 (Reuters) - Evotec SE <EVTG.DE>::DGAP-NEWS: EVOTEC EXPANDS ITS IPSC DISCOVERY PLATFORM.ACQUIRED ASSETS FROM NCARDIA AG INCLUDE IP PORTFOLIO, IPSC-BASED CELLULAR PRODUCTS AND AN EXPERIENCED STEM CELL BIOLOGY TEAM.ACQUIRED ASSETS INCLUDE INTELLECTUAL PROPERTY RELEVANT FOR IPSC-BASED PHENOTYPIC DRUG DISCOVERY, AN EXISTING CELLULAR PRODUCT BUSINESS AROUND IPSC-DERIVED CELLS, AS WELL AS 17 STRONG TEAM OF STEM CELL BIOLOGY EXPERTS OPERATING FROM LABORATORIES AT BIOCAMPUS COLOGNE.

Evotec And Venture Capital Consortium Form Breakpoint Therapeutics GmbH

July 8 (Reuters) - Evotec SE <EVTG.DE>::DGAP-NEWS: EVOTEC AND VENTURE CAPITAL CONSORTIUM FORM 'BREAKPOINT THERAPEUTICS GMBH'.FORMATION OF BREAKPOINT THERAPEUTICS GMBH, A SPIN-OFF COMPANY FOCUSING ON DEVELOPMENT OF EVOTEC'S DNA DAMAGE RESPONSE PORTFOLIO.ANNOUNCED FORMATION OF BREAKPOINT THERAPEUTICS GMBH, A SPIN-OFF COMPANY FOCUSING ON DEVELOPMENT OF EVOTEC'S DNA DAMAGE RESPONSE.SPIN-OFF COMPANY FOCUSING ON DEVELOPMENT OF EVOTEC'S DNA DAMAGE RESPONSE ("DDR") PORTFOLIO.GOAL OF SPIN-OFF COMPANY IS TO ACCELERATE EARLY PROJECTS THROUGH DISCOVERY AND PRE-CLINICAL DEVELOPMENT.TO DELIVER FIRST IND-READY DRUG IN 2022.BREAKPOINT THERAPEUTICS' MISSION IS TO DEVELOP FIRST AND BEST-IN-CLASS ONCOLOGY DRUGS THAT INTERFERE WITH DNA REPAIR AND REPLICATION STRESS PATHWAYS TO FACILITATE CURE OF THERAPY-RESISTANT CANCERS.BREAKPOINT THERAPEUTICS WILL INITIALLY FOCUS ON ADVANCING MULTIPLE DRUG DISCOVERY PROGRAMMES INITIATED AT EVOTEC THAT ADDRESS HIGH UNMET MEDICAL NEEDS OF DIFFERENT PATIENT GROUPS.GOAL OF SPIN-OFF COMPANY IS TO ACCELERATE EARLY PROJECTS THROUGH DISCOVERY AND PRE-CLINICAL DEVELOPMENT AND EXPECT TO DELIVER FIRST IND-READY DRUG IN 2022.EARLY STAGE FUNDING AMOUNTING TO EUR 30 M WILL BE COVERED BY A RENOWNED INTERNATIONAL INVESTOR CONSORTIUM LED BY MEDICXI, A LIFE SCIENCES-FOCUSED INVESTMENT FIRM, TAIHO VENTURES, LLC ("TAIHO"), VENTURE CAPITAL ARM OF TAIHO PHARMACEUTICAL, AND EVOTEC.EVOTEC WILL HOLD BELOW 50% OF COMPANY AND CONSOLIDATE AT EQUITY ACCORDINGLY..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up